Myra Vision Stock

Myra Vision develops a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma.

Sign up today and learn more about Myra Vision Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Myra Vision Stock

Myra Vision develops a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma. It seeks to provide IOP control and fill gaps in therapies for people with moderate to severe glaucoma.

Funding History

October 2019$3.2M
January 2021$5.3M
June 2021$17.0M
June 2023$25.0M

Management

President, CEO

Robert Chang

Chairman

Amr Salahieh

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo